Key Takeaways
- FDA's budget authority for fiscal year 2026 will continue to allow for user fees, according to a preliminary budget plan developed by the White House...
The US Food and Drug Administration’s tax-payer funding would decline in fiscal year 2026 compared to 2025 but not enough to trigger suspension of user fees, under a preliminary internal...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?